Communiqués Lexicon Pharmaceuticals, Inc.

Actions

LXRX

US5288723027

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 16:12:49 31/07/2026			Varia. 5j.	Varia. 1 janv.
2,275 ^USD	-2,78%		+0,44%	+100,00%

27/07	Lexicon Pharmaceuticals achève les inclusions dans l’étude pivot de phase 3 SONATA-HCM sur la sotagliflozine chez des patients atteints de cardiomyopathie hypertrophique symptomatique, obstructive et non obstructive	CI
27/07	Lexicon Pharmaceuticals achève le recrutement pour l'essai d'un traitement potentiel de la cardiomyopathie hypertrophique	MT

Communiqués

30/07	Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026	GL
27/07	Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)	GL
03/06	Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions	GL
03/06	Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions	AQ
28/05	Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference	GL
12/05	Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference	AQ
08/05	Lexicon Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Lexicon: Q1 Earnings Snapshot	AQ
07/05	Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates	GL
04/05	Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital	GL
30/04	Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026	AQ
17/04	Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting	AQ
24/03	Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo	AQ
23/03	Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851	AQ
11/03	Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes	AQ
05/03	Lexicon: Q4 Earnings Snapshot	AQ
05/03	Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates	AQ
03/03	Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences	AQ
26/02	Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026	AQ
06/02	Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement	AQ
30/01	Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement	AQ
29/01	Lexicon Announces Proposed Public Offering of Common Stock	AQ
23/01	Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary	AQ
21/01	Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain	GL
12/01	Lexicon Pharmaceuticals Publishes Relief is Possible, Ensuring Access to Effective Treatments for Chronic Pain	AQ